OR WAIT null SECS
Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.
Eli Lilly and Company announced on Jan. 28, 2022 that it plans to invest more than $1 billion to create a new manufacturing site in Concord, N.C., which will use the latest technology to manufacture parenteral products and devices. The new facility will also increase the company's manufacturing capacity and create nearly 600 new jobs.
Lilly’s investment activity in North Carolina includes its previous investment of $470 million in 2020 to build up North Carolina's Research Triangle Park. In conjunction with the Research Triangle Park site, the new facility in Concord will allow the company to strengthen relationships with local governments and universities. The nearly 600 new jobs Lilly plans to create at the new facility in Concord will be for highly skilled workers such as scientists, engineers, and manufacturing personnel. In addition, an estimated 500 additional positions will be needed while the facility is under construction.
Over the past five years, Lilly has invested more than $4 billion in global manufacturing, including more than $2 billion in the United States. The company also announced plans on Jan. 28, 2022 to invest $500 million in a new biopharmaceutical manufacturing facility in Limerick, Ireland. Lilly also anticipates making additional future investments in manufacturing to meet growth in demand from potential new medicines to treat diabetes, Alzheimer's disease, cancer, and autoimmune conditions.
"Expanding our manufacturing footprint in North Carolina enables us to continue to produce today's medicines while providing additional capacity to manufacture the medicines of tomorrow. We are pleased to again partner with North Carolina to bring jobs to American workers and provide more medicines that patients need to address health challenges," said Edgardo Hernandez, senior vice-president and president, Lilly Manufacturing Operations, in a company press release.
Source: Eli Lilly and Company